Back to News
Market Impact: 0.5
Corcept's Lifyorli Gets Positive EU Opinion For Platinum-Resistant Ovarian Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Corcept Therapeutics said the EMA's Committee for Medicinal Products for Human Use recommended approval of relacorilant in combination with nab-paclitaxel for patients with platinum-resistant ovarian cancer. The positive CHMP opinion is a major regulatory milestone that advances relacorilant toward European commercialization and could materially expand Corcept's oncology opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
CORT0.82
More News
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- California’s Bay Area debates data centres ahead of US midterm elections
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- ‘Fastest entertainment property in history’: GTA VI arrives to test a thin November box office